FBO#0681
A - Research and Development
AWARDS - October 9, 2003
- NO1-AG-3-1010 - $209,628 (Base); $554,038 including all options
NEW THERAPEUTIC TARGETS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASE - PHARMACEUTICAL FORMULATION OF DRUGS
SRI International, 333 Ravenwood Avenue, Menlo Park, CA 94025-3493,
- NO1-AG-3-1008 - $918,781 (Base); $2,425,080 including all options
NEW THERAPEUTIC TARGETS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASE - PRECLINICAL TOXICOLOGY
SRI International, 333 Ravenwood Avenue, Menlo Park, CA 94025-3493
- NO1-AG-3-1013 - $219,605 (Base); $549,231 including all options
DEVELOPMENT AND MAINTENANCE OF AN AGED NON-HUMAN PRIMATE TISSUE BANK
BioReliance Corporation, 14920 Broschart Road, Rockville, MD 20850
- F33615-03-D-2417 - $49,405,000.00
ROBUST SCRAMJET
Aerojet-General Corporation, Highway 50 & Aerojet Road, Rancho Cordova, CA 95742-6401,
- DAAE0703CL148 - $509,600.00
OTHER RESEARCH & DEVELOPMENT
THE REGENTS OF THE UNIVERSITY OF MICHIGAN,DIVISION OF RESEARCH DEVELOPMENT AND ADMINISTRATION,1058 WOLVERINE TOWER - DRDA,3003 S. STATE ST.,ANN ARBOR,MI,48109-1274
| This Issue's Index | Today's FBO Daily Index Page |
Created on 07-Oct-2003 by Loren Data Corp. -- info@fbodaily.com